Rallybio Corp (RLYB): EBITDA
-$32.97M
Year ended 2025-12-31
-$27.68M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$32.97M | n/m | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | -$60.37M | n/m | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | -$78.78M | n/m | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | -$67.72M | n/m | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | -$45.54M | n/m | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | -$25.24M | n/a | 2022-03-15, From 2020-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Rallybio Corp (RLYB) | 2025-12-31 | -$32.97M | n/m |
| Onconetix, Inc. (ONCO) | 2025-12-31 | -$17.84M | n/m |
| Hyperion Defi, Inc. (HYPD) | 2024-12-31 | -$47.61M | n/m |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | -$28.87M | n/m |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | -$47.81M | n/m |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | -$7.72M | n/m |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | -$11.92M | n/m |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | -$11.79M | n/m |
| Polomar Health Services, Inc. (PMHS) | 2025-12-31 | -$776.9K | n/m |
Compare RLYB, ONCO, HYPD, RFL side by side · Screen every company in Pharmaceutical Preparations ↗